The study [Abstract #2], "Infusing Chilled Saline Through the Intraosseous Route is Equivalent to Infusion Through the Intravenous Route in Reducing the Core Temperature in Swine," investigated whether Intraosseous (IO) vascular access may be effectively used to infuse chilled saline to achieve therapeutic hypothermia (TH) as an alternative to peripheral intravenous (IV) access. The study found that IO and IV temperature reductions were statistically equivalent and concluded no clinical or statistical difference between IV and IO when comparing the two routes for infusion of chilled saline for therapeutic hypothermia.
The research study used the EZ-IO® Intraosseous Infusion System – the first battery-powered device to establish immediate vascular access and the only IO device which is FDA cleared for humeral insertion. The EZ-IO is used by 90 percent of US advanced life support ambulances and over half of US Emergency Departments, as well as the US Military.
Established in 2001, Vidacare Corporation is the developer of a broad technology platform that is defining the field of intraosseous medicine. Current products include the EZ-IO® Intraosseous Infusion System, the OnControl™ Bone Marrow System and the OnControl™ Bone Access System, and applications include vascular access, emergency and disaster medicine, oncology and spinal surgery. Vidacares focus on enhancing clinical efficacy, patient safety and comfort, and reducing complications and their associated costs, has resulted in its devices becoming the recognized technology standard. Privately held, the company is based in San Antonio, Texas, and its products are marketed in over 50 countries worldwide. www.vidacare.com
Posted by Sean Fenske, Editor-in-Chief, MDT